U.S. markets closed

Exact Sciences Corporation (EXAS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
65.94-0.91 (-1.36%)
At close: 04:00PM EDT
66.00 +0.06 (+0.09%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close66.85
Bid65.00 x 1000
Ask65.89 x 1100
Day's Range65.73 - 67.35
52 Week Range29.27 - 100.77
Avg. Volume1,349,414
Market Cap11.913B
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-2.33
Earnings DateNov 01, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.47
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EXAS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exact Sciences Corporation
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more

    Uranium ETF shines while ARK Genomic Revolution ETF struggles

    In a striking contrast of fortunes in the Exchange-Traded Fund (ETF) market on Friday, the Uranium ETF outperformed its peers, while the ARK Genomic Revolution ETF struggled.

  • Business Wire

    Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

    SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.

  • Motley Fool

    Where Will Exact Sciences Be in 5 Years?

    Over the past five years, Exact Sciences (NASDAQ: EXAS) hasn't delivered great returns. Exact Sciences develops cancer diagnostic tests. It is best known for its at-home, noninvasive colorectal cancer screening option, Cologuard.